<健保新聞>健保新增多種給付藥品！估10萬名病友受惠

健保署今（14）日表示，去年健保總共收載超過34種新藥，並擴增了18類疾病藥品的給付範圍。當中以癌藥最多占40%，範圍涵蓋乳癌、肺癌、肝癌、大腸直腸癌、胰腺癌等12種癌別。今年初健保並增加給付第二代肝癌標靶新藥以及非小細胞肺癌口服化療藥品，另外也放寬B型肝炎用藥條件，估算超過10萬名病友可享受新藥給付帶來的治療效益。

👉近5年增加給付近百項新藥 在台治療不輸歐美
健保署指出，以107年共1千957億元藥費為例，花費最多的藥品是抗腫瘤與免疫調節劑，約有389億元，占整體藥費22%，成長率排名第1。其次為心臟血管用藥、全身性抗感染劑、胃腸道及代謝用藥，分別占整體藥費約16%、15%及14%。其中高居國人10大死因之首的癌症，近5年就增加給付了100項新藥，占所有在台上市癌藥的7成，我國癌友接受新藥治療的機會並不輸給歐美先進國家。

👉利用雲端醫療資訊系統 管控用藥狀況避浪費
健保署補充，在健保財源尚無法擴充下，新藥的給付對象及條件難免有所限制，因此健保也採取風險分攤機制，要求廠商負擔部分藥費；同時也利用雲端醫療資訊系統，積極管控重複用藥與檢測，避免不必要的浪費，將節省下來的經費用來給付更多其他新藥，或是放寬尚未滿足醫療需求疾病的藥品給付限制，讓更多病友獲得接受新藥治療的機會。

👉與專家、醫界團體共同努力 健保署盼達最佳效益
「健保是台灣之光，也是台灣之寶」，健保署強調，健保的信念是有「價值」的藥品與醫療行為要有合理給付，在財務可承擔下為病患爭取權益。健保署會站在照護病人的立場，以實證醫學為基礎推動精準醫療，期盼與藥物擬訂會議代表（含專家、醫界團體、付費者代表、病友團體及藥廠）一起努力，讓每個藥品給付均能達到最佳的效益。

●開放給付藥品重點摘述

乳癌：放寬雙標靶藥物使用條件，新增CDK4/6口服標靶藥物

肺癌：擴增給付ALK與ROS-1基因突變標靶藥物，新增口服化療藥品

肝細胞癌：給付第二代肝癌標靶新藥，並放寬藥物使用條件

大腸直腸癌：新增口服化療藥品

腎細胞癌：收載對VEGFR-TKI或mTOR無效之多標靶新藥

攝護腺癌：給付放射性鐳治療，並擴增荷爾蒙藥物治療範圍

胰腺癌：收載新劑型紫杉醇化療藥物

白血病：新增抗CD22或費城染色體變異之數項標靶藥物，並放寬用藥規定，增加臨床適用範圍

癌症免疫新藥：開放給付於黑色素瘤、肺癌、何杰金氏淋巴瘤、頭頸癌、泌尿道癌、胃癌、肝癌與腎癌等8種癌別，其中胃癌與肝癌的給付比其他國家為早

C型肝炎：擴大給付範圍，不設限給付條件

B型肝炎：放寬給付條件，增加臨床適用範圍

疱疹：全身性抗疱疹病毒劑不再限制病患族群及發生部位

風濕免疫疾病：放寬給付年齡限制並新增免疫調節新藥

罕見疾病：新增高雪氏症、肺動脈高壓等多項罕病新藥

另有糖尿病、高血脂、後天免疫缺乏症候群、思覺失調症、抗生素等多項新藥與給付規定放寬。

資訊來源：
https://tw.news.yahoo.com/%E5%81%A5%E4%BF%9D%E6%96%B0%E5%A2%9E%E5%A4%9A%E7%A8%AE%E7%B5%A6%E4%BB%98%E8%97%A5%E5%93%81-%E4%BC%B010%E8%90%AC%E5%90%8D%E7%97%85%E5%8F%8B%E5%8F%97%E6%83%A0-035300367.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAIcBTIn2ycCDFrcQL2OZ6-zYSfLSUGsNNKWyVqSrAalbQzfWzIJDLb50gStv_8MJzB87figT1Dch_89yDeM0HiBK4x9pM-eK6ZK2Mzn80SfNd4ttAEnfMxb9dqV0RdUzgmo_VjvEyu77AzW-bOt2YVawMyzcAlgSKWOYq00q2pbm

希望大家可以幫吓可仁啦😢 我希望個個小朋友都可以健康快樂咁成長，可以一齊去公園玩

【最新消息：募捐行動已於2018年12月3日結束】中大校友慈善基金感謝各界慷慨支持，募捐行動已結束。所得善款將支持張可仁及患上相類疾病需免疫治療的其他6位病童。

詳情請參閱中大校友慈善基金網頁：https://www.facebook.com/cuhkacf.org/posts/589827338133781

-------------------------------------------------------------------------------------
(2018/11/22)

中大醫學院向大家作出緊急呼籲，支持我們2000年的醫科畢業生張俊傑醫生，拯救他只有17個月大的兒子張可仁的性命。

可仁早於出生第4天時已被診斷罹患一種罕有心臟病「主動脈狹窄」(Coarctation of Aorta)，需要接受緊急手術。極之不幸的是，可仁最近再被確診患上「第四期神經母腫瘤」(Stage IV Neuroblastoma)，目前可仁的頭骨至腰椎和盆骨均受到癌細胞擴散，脊髓神經線受到癌細胞壓住，痛楚非常，並有癱瘓的危機，癌細胞更正轉移至骨髓。

可仁現時正住在威爾斯親王醫院兒童癌症中心隔離病房，極容易受到感染。他已開始接受化療，而治療方案將包括化療、手術、放射治療、骨髓移植、免疫治療，治療時間約一年至一年半。他完成化療、手術和放射治療後，會進行骨髓移植，之後需要免疫療法，這可大大提高存活率，由20%升至50%。

然而，免疫治療需要病人自費，所需費用高達港幣200萬元。張醫生另一兒子患有自閉症，太太辭掉小學主任一職，全職照顧兩位小朋友，並要照顧父母親，經濟上未能承擔高昂的醫療費用。

中大醫學院2000年畢業同學會發起是次籌款，目的包括：
1. 為可仁進行骨髓移植後的免疫治療；
2. 引發社會人士及政府對兒童罕有癌症治療的關注。

查詢：
香港中文大學校友慈善基金
電郵：info@cuhkacf.org
電話：2180 4316

-------------------------------------------------------------------------------------

【Fundraising Campaign Completed on 3 December 2018】According to CUHK Alumni Charity Foundation, the fundraising campaign for Mark CHEUNG Ho Yan has completed. The fund raised will be used to support the immunotherapy of Mark and 6 other patients who are suffered from the same disease. Thank you for all your kind-hearted support and generosity.

-------------------------------------------------------------------------------------

(2018/11/22)

This is an urgent appeal for your generosity to save the life of the 17-month-old son of Dr. CHEUNG Chun Kit, our medical alumnus of Class 2000.

Dr. Cheung Chun Kit is a CUHK medical graduate of Year 2000. His younger son, Cheung Ho Yan Mark, has recently been diagnosed to have Stage IV Neuroblastoma in November 2018, and is in an emergency need of donation to provide the necessary funding to support the life-saving yet expensive immunotherapy.

Mark was presented to his paediatrician for fever and cough in late October 2018. His cough resolved with treatment but his fever never completely went away. Two days prior to his diagnosis, Mark was more clingy than usual and did not like to walk. On a video clip, Mark was noted to have foot drop, a very significant red flag which may indicate a compression on the spinal cord. Emergency scans were immediately performed that night, and Mark was found to have a large tumour on the left side of his abdomen. The aggressive tumour had already spread silently to the back of his skull, his spine, his hips and had compressed his nerves which control his lower limbs, resulting in pain on standing and difficulty in walking. Mark is facing an imminent risk of paralysis.

Mark is diagnosed to have a rare childhood cancer which is called Stage IV neuroblastoma, a cancer which typically presents at late stage because it arises deep in the abdomen. To cure his aggressive cancer, Mark needs to survive through rounds of intensive chemotherapy, radiotherapy, surgery, bone marrow transplant, and finally, immunotherapy. The whole treatment duration lasts 1.5 to 2 years. To completely eradicate all cancer cells, immunotherapy will be needed to boost Mark’s survival from 20% to 50%. However, immunotherapy is a self-financed treatment in the public hospital and the treatment costs could be up to 2 million.

Such close encounter with death is not the first time for Mark. At the first week of life, Mark was diagnosed to have a rare heart problem called “Coarctation of Aorta”. Mark had received life-saving surgery to reestablish the blood flow across his aorta, the major blood vessel that allows blood to go from the heart to the brain and the rest of the body. In a report published in 2002, only 67 cases with dual heart condition and neuroblastoma were reported, giving an odd of 1 in 100 million for a child to be hit by these two rare diseases. Scientists have not yet completely understood the mechanisms that may cause the two conditions to appear in a single child.

It never rains but pours that Mark’s elder brother, now 5 years old, was diagnosed to have autism at around age 2. To enable the elder brother to have intensive training to improve his outcome and development, Mark’s mommy quit her job as a primary school teacher since the diagnosis of autism was made for his elder brother. Dr. Cheung, who is a medical doctor for the elderly, became the sole bread-winner of his family.

CUHK Medical Graduates of Year 2000 have initiated a fund-raising campaign for Mark and his family with the following two objectives:

1. To appeal for donation to support the costs of immunotherapy for Mark
2. To increase the public awareness on the grave needs of children with cancers

Enquiries:
CUHK Alumni Charity Foundation Limited
Email: info@cuhkacf.org
Telephone: 2180 4316

🙏🏻🙏🏻🙏🏻

【最新消息：募捐行動已於2018年12月3日結束】中大校友慈善基金感謝各界慷慨支持，募捐行動已結束。所得善款將支持張可仁及患上相類疾病需免疫治療的其他6位病童。

詳情請參閱中大校友慈善基金網頁：https://www.facebook.com/cuhkacf.org/posts/589827338133781

-------------------------------------------------------------------------------------
(2018/11/22)

中大醫學院向大家作出緊急呼籲，支持我們2000年的醫科畢業生張俊傑醫生，拯救他只有17個月大的兒子張可仁的性命。

可仁早於出生第4天時已被診斷罹患一種罕有心臟病「主動脈狹窄」(Coarctation of Aorta)，需要接受緊急手術。極之不幸的是，可仁最近再被確診患上「第四期神經母腫瘤」(Stage IV Neuroblastoma)，目前可仁的頭骨至腰椎和盆骨均受到癌細胞擴散，脊髓神經線受到癌細胞壓住，痛楚非常，並有癱瘓的危機，癌細胞更正轉移至骨髓。

可仁現時正住在威爾斯親王醫院兒童癌症中心隔離病房，極容易受到感染。他已開始接受化療，而治療方案將包括化療、手術、放射治療、骨髓移植、免疫治療，治療時間約一年至一年半。他完成化療、手術和放射治療後，會進行骨髓移植，之後需要免疫療法，這可大大提高存活率，由20%升至50%。

然而，免疫治療需要病人自費，所需費用高達港幣200萬元。張醫生另一兒子患有自閉症，太太辭掉小學主任一職，全職照顧兩位小朋友，並要照顧父母親，經濟上未能承擔高昂的醫療費用。

中大醫學院2000年畢業同學會發起是次籌款，目的包括：
1. 為可仁進行骨髓移植後的免疫治療；
2. 引發社會人士及政府對兒童罕有癌症治療的關注。

查詢：
香港中文大學校友慈善基金
電郵：info@cuhkacf.org
電話：2180 4316

-------------------------------------------------------------------------------------

【Fundraising Campaign Completed on 3 December 2018】According to CUHK Alumni Charity Foundation, the fundraising campaign for Mark CHEUNG Ho Yan has completed. The fund raised will be used to support the immunotherapy of Mark and 6 other patients who are suffered from the same disease. Thank you for all your kind-hearted support and generosity.

-------------------------------------------------------------------------------------

(2018/11/22)

This is an urgent appeal for your generosity to save the life of the 17-month-old son of Dr. CHEUNG Chun Kit, our medical alumnus of Class 2000.

Dr. Cheung Chun Kit is a CUHK medical graduate of Year 2000. His younger son, Cheung Ho Yan Mark, has recently been diagnosed to have Stage IV Neuroblastoma in November 2018, and is in an emergency need of donation to provide the necessary funding to support the life-saving yet expensive immunotherapy.

Mark was presented to his paediatrician for fever and cough in late October 2018. His cough resolved with treatment but his fever never completely went away. Two days prior to his diagnosis, Mark was more clingy than usual and did not like to walk. On a video clip, Mark was noted to have foot drop, a very significant red flag which may indicate a compression on the spinal cord. Emergency scans were immediately performed that night, and Mark was found to have a large tumour on the left side of his abdomen. The aggressive tumour had already spread silently to the back of his skull, his spine, his hips and had compressed his nerves which control his lower limbs, resulting in pain on standing and difficulty in walking. Mark is facing an imminent risk of paralysis.

Mark is diagnosed to have a rare childhood cancer which is called Stage IV neuroblastoma, a cancer which typically presents at late stage because it arises deep in the abdomen. To cure his aggressive cancer, Mark needs to survive through rounds of intensive chemotherapy, radiotherapy, surgery, bone marrow transplant, and finally, immunotherapy. The whole treatment duration lasts 1.5 to 2 years. To completely eradicate all cancer cells, immunotherapy will be needed to boost Mark’s survival from 20% to 50%. However, immunotherapy is a self-financed treatment in the public hospital and the treatment costs could be up to 2 million.

Such close encounter with death is not the first time for Mark. At the first week of life, Mark was diagnosed to have a rare heart problem called “Coarctation of Aorta”. Mark had received life-saving surgery to reestablish the blood flow across his aorta, the major blood vessel that allows blood to go from the heart to the brain and the rest of the body. In a report published in 2002, only 67 cases with dual heart condition and neuroblastoma were reported, giving an odd of 1 in 100 million for a child to be hit by these two rare diseases. Scientists have not yet completely understood the mechanisms that may cause the two conditions to appear in a single child.

It never rains but pours that Mark’s elder brother, now 5 years old, was diagnosed to have autism at around age 2. To enable the elder brother to have intensive training to improve his outcome and development, Mark’s mommy quit her job as a primary school teacher since the diagnosis of autism was made for his elder brother. Dr. Cheung, who is a medical doctor for the elderly, became the sole bread-winner of his family.

CUHK Medical Graduates of Year 2000 have initiated a fund-raising campaign for Mark and his family with the following two objectives:

1. To appeal for donation to support the costs of immunotherapy for Mark
2. To increase the public awareness on the grave needs of children with cancers

Enquiries:
CUHK Alumni Charity Foundation Limited
Email: info@cuhkacf.org
Telephone: 2180 4316